Share on StockTwits

United Therapeutics (NASDAQ:UTHR) has been given a consensus recommendation of “Hold” by the fifteen ratings firms that are presently covering the company, Analyst RN reports. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $97.54.

In other United Therapeutics news, CEO Martine A. Rothblatt unloaded 3,833 shares of the stock on the open market in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $87.23, for a total transaction of $334,352.59. The transaction was disclosed in a document filed with the SEC, which is available at this link.

UTHR has been the subject of a number of recent research reports. Analysts at RBC Capital reiterated a “sector perform” rating on shares of United Therapeutics in a research note on Monday, June 16th. They now have a $90.00 price target on the stock. Separately, analysts at Credit Suisse upgraded shares of United Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, June 16th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Tuesday, May 27th. They now have a $104.00 price target on the stock.

Shares of United Therapeutics (NASDAQ:UTHR) traded up 0.02% on Monday, hitting $89.47. The stock had a trading volume of 72,597 shares. United Therapeutics has a 52-week low of $66.01 and a 52-week high of $116.65. The stock has a 50-day moving average of $95.56 and a 200-day moving average of $99.16. The company has a market cap of $4.310 billion and a P/E ratio of 19.43.

United Therapeutics (NASDAQ:UTHR) last released its earnings data on Tuesday, April 29th. The company reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter in the previous year, the company posted $1.19 earnings per share. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. Analysts expect that United Therapeutics will post $7.77 EPS for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.